My main research interests are in genital and urinary cancers, and I lead a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med (2019) 380(12):1116-1127. PMID: 30779529
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet (2019) 393(10189):2404-2415. PMID: 31079938
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature (2018) 554(7693):544-548. PMID: 29443960
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med (2018) 24(6):749-757. PMID: 29867230
I am the lead for solid tumor research at Barts Cancer Institute. I also lead the genitourinary (GU) cancer group at BCI.
My work focuses on a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies. They exploit functional imaging and tissue collection.
Alongside these trials, our research focuses on correlation of novel biomarkers and aims to define markers that are of prognostic value and can predict response or resistance to therapy.
I have written over 100 peer review papers in this area and have grant income from national and international funding bodies.
I am on the editorial board of a number of journals and am part of the faculty for the major global oncology meetings.
Genomic landscape of platinum resistant and sensitive testicular cancers Loveday C, Litchfield K, Proszek PZ et al. Nature Communications (2020) 11(7)
Immune checkpoint inhibition in urothelial carcinoma Szabados B, Powles T The Lancet (2020) 395(7) 1522-1523
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade Yuen KC, Liu LF, Gupta V et al. Nature medicine (2020) 26(7) 693-698
ATLANTIS: A randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer Fulton B, Jones R, Powles T et al. Trials (2020) 21(7)
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial Birtle A, Johnson M, Chester J et al. The Lancet (2020) 395(7) 1268-1277
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer[Formula presented] Kamoun A, de Reyniès A, Allory Y et al. European Urology (2020) 77(7) 420-433
Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data de Bruijn R, Wimalasingham A, Szabados B et al. European urology oncology (2020) 3(7) 168-173
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials Chalabi M, Cardona A, Nagarkar DR et al. Annals of Oncology (2020) 31(7) 525-531
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434–5 Kamoun A, de Reyniès A, Allory Y et al. European Urology (2020) 77(7) 436-438
The efficacy of sunitinib treatment of renal cancer cells is associated with the Protein PHAX in vitro Al-Lamki RS, Hudson NJ, Bradley JR et al. Biology (2020) 9(7)For additional publications, please click here
I qualified from St Bartholomew’s Medical School in 1996 and trained in medical oncology at Imperial College. I completed post-graduate training in oncology in 2005 and received an MD from the University of London in 2006. My thesis was in mechanisms of resistance to therapy in urology cancers.